i mentioned theme earlier pharmagossip merrill goozner among others banging drum much longer i problem one hand pharmaceutical companies bemoan allegedly huge costs research development hand lack innovative developments example fda approved invega treatment schizophrenia active ingredient although drug contains active substance never approved fda substance active metabolite old drug atypical antipsychotic risperdal risperidone marketed treating schizophrenia developed invega janssen also developed markets risperdal coincidentally risperdal soon going patent generic competition swoops janssen wants keep patients high cost med course switching risperdal invega likely clinical advantages invega risperdal nope similar risperdal expect notable differences scientifically would course made better sense develop something different science benefiting patients